CA2627351C - Lipophilic vehicle-based dual controlled release matrix system - Google Patents

Lipophilic vehicle-based dual controlled release matrix system Download PDF

Info

Publication number
CA2627351C
CA2627351C CA2627351A CA2627351A CA2627351C CA 2627351 C CA2627351 C CA 2627351C CA 2627351 A CA2627351 A CA 2627351A CA 2627351 A CA2627351 A CA 2627351A CA 2627351 C CA2627351 C CA 2627351C
Authority
CA
Canada
Prior art keywords
agents
rate controlling
soft capsule
matrix
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2627351A
Other languages
English (en)
French (fr)
Other versions
CA2627351A1 (en
Inventor
Karunakar Sukuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patheon Softgels Inc
Original Assignee
Banner Pharmacaps Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Pharmacaps Inc filed Critical Banner Pharmacaps Inc
Publication of CA2627351A1 publication Critical patent/CA2627351A1/en
Application granted granted Critical
Publication of CA2627351C publication Critical patent/CA2627351C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2627351A 2005-10-26 2006-10-26 Lipophilic vehicle-based dual controlled release matrix system Expired - Fee Related CA2627351C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73051405P 2005-10-26 2005-10-26
US60/730,514 2005-10-26
PCT/US2006/041722 WO2007050724A2 (en) 2005-10-26 2006-10-26 Lipophilic vehicle-based dual controlled release matrix system as capsule fill

Publications (2)

Publication Number Publication Date
CA2627351A1 CA2627351A1 (en) 2007-05-03
CA2627351C true CA2627351C (en) 2012-05-01

Family

ID=37968540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2627351A Expired - Fee Related CA2627351C (en) 2005-10-26 2006-10-26 Lipophilic vehicle-based dual controlled release matrix system

Country Status (6)

Country Link
US (1) US8293270B2 (enExample)
EP (1) EP1951208A2 (enExample)
JP (2) JP5406529B2 (enExample)
CN (1) CN101351196B (enExample)
CA (1) CA2627351C (enExample)
WO (1) WO2007050724A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
PT2679228T (pt) 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
EP3225243B1 (en) 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101959952B1 (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2689434C (en) * 2007-06-04 2017-09-26 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
WO2009067666A2 (en) * 2007-11-21 2009-05-28 Tennessee Technological University Thermoresponsive microparticle composite hydrogels for electrophoresis
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
CN102196810B (zh) * 2008-10-22 2013-11-06 参天制药株式会社 改善肠吸收性的药物组合物
ES2783980T3 (es) 2010-03-29 2020-09-21 Opko Ireland Global Holdings Ltd Métodos y composiciones para la reducción de niveles de paratiroides
WO2013076305A1 (en) 2011-11-25 2013-05-30 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system
US20150250751A1 (en) * 2012-10-16 2015-09-10 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
US20150238451A1 (en) * 2012-10-19 2015-08-27 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
ES2713157T3 (es) 2014-02-28 2019-05-20 Banner Life Sciences Llc Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US10772842B2 (en) 2015-01-09 2020-09-15 Patheon Softgels Inc. Abuse-deterrent opioids
US10772841B2 (en) 2014-04-07 2020-09-15 Patheon Softgels Inc. Opioid abuse-deterrent controlled release formulations
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
US20200022911A1 (en) * 2016-04-26 2020-01-23 Symbiotic Health Inc. Stable macroemulsion for oral delivery of solubilized peptides, protein, and cellular therapeutics
EP3765002B1 (en) * 2018-03-15 2025-03-05 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
CN113301884A (zh) * 2018-09-13 2021-08-24 夫特弗制药私人有限公司 非水性化疗口服悬浮液
WO2020074361A1 (en) * 2018-10-08 2020-04-16 Chanelle Pharmaceuticals Manufacturing Ltd. A soft-gel capsule formulation, method of manufacture and use thereof
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2016A (en) * 1841-03-26 Mode of constructing fireplaces and chimney-staoks ii
US4424235A (en) * 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
CA2017916C (en) 1989-06-07 1999-02-02 Minoru Aoki Etoposide preparations
CA2107678A1 (en) * 1991-04-08 1992-10-09 Kouichi Nakamichi Capsule
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
EP0725626A1 (en) * 1993-10-29 1996-08-14 RECKITT & COLMAN PRODUCTS LIMITED Gelatin capsule fill able to foam
GB9322314D0 (en) 1993-10-29 1993-12-15 Scherer Ltd R P Foam generating capsules
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
FR2748209B1 (fr) * 1996-05-06 1998-06-05 Adir Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
US6027746A (en) 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
IT1291362B1 (it) * 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
JP4139909B2 (ja) * 1997-06-12 2008-08-27 キャタレント・ジャパン株式会社 ソフトカプセル用基剤
GB2328443B (en) * 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
BE1011363A3 (fr) * 1997-09-11 1999-08-03 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee.
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
GB2331458B (en) 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
AU2117399A (en) 1998-01-20 1999-08-02 Applied Analytical Industries, Inc. Oral liquid compositions
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
MXPA02003190A (es) 1999-09-27 2002-09-30 American Cyanamid Co Formulacion para portadores farmaceuticos.
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US6607736B2 (en) 1999-12-20 2003-08-19 Shiseido Company, Ltd. Skin preparations for external use
US6491950B1 (en) * 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
US20030105141A1 (en) 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
CA2472188C (en) 2002-01-18 2011-06-21 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
IL164163A0 (en) 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
FR2838349B1 (fr) * 2002-04-15 2004-06-25 Laurence Paris Compositions liquides pour capsules molle a liberation prolongee et leur procede de fabrication
AU2003234145A1 (en) * 2002-04-18 2003-11-03 Alkermes, Inc. System for enhanced targeted delivery
US20040033257A1 (en) 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
CA2491572C (en) 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
EP2772250B1 (en) 2002-10-01 2016-09-28 Banner Life Sciences LLC Enteric composition for the manufacture of soft capsule wall
WO2005009409A2 (en) 2003-07-17 2005-02-03 Banner Pharmacaps, Inc. Controlled release preparations
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
CA2552611A1 (en) * 2004-01-09 2005-08-04 Wyeth Microemulsions for pharmaceutical compositions
US20060286172A1 (en) 2005-06-03 2006-12-21 Anu Mahashabde Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same

Also Published As

Publication number Publication date
US20070092560A1 (en) 2007-04-26
WO2007050724A2 (en) 2007-05-03
US8293270B2 (en) 2012-10-23
CN101351196A (zh) 2009-01-21
JP2009513657A (ja) 2009-04-02
JP5406529B2 (ja) 2014-02-05
EP1951208A2 (en) 2008-08-06
JP2013216681A (ja) 2013-10-24
CA2627351A1 (en) 2007-05-03
WO2007050724A3 (en) 2007-09-20
CN101351196B (zh) 2013-07-03

Similar Documents

Publication Publication Date Title
CA2627351C (en) Lipophilic vehicle-based dual controlled release matrix system
CA2627292C (en) Hydrophilic vehicle-based dual controlled release matrix system
US10632205B2 (en) Pharmaceutical composition having reduced abuse potential
US5433951A (en) Sustained release formulation containing captopril and method
EP1605916A1 (en) Solvent system of hardly soluble drug with improved elution rate
BR112021001345A2 (pt) formulações multiparticuladas de canabinoides
MX2011006307A (es) Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
JP2007509155A (ja) クエチアピンを含有する薬剤
WO2009066146A2 (en) Stable solutions of sparingly soluble actives
EA035515B1 (ru) Композиции на основе дейтерированного домперидона и способы терапии расстройств
SK7342000A3 (en) Formulations comprising dissolved paroxetine
AU2005330320A1 (en) Improved formulations of fenofibrate containing menthol or a PEG/poloxamer mixture
US20020032220A1 (en) Formulations comprising dissolved paroxetine
CN106572980A (zh) 包含他喷他多的防篡改即释胶囊制剂
MX2008005470A (en) Lipophilic vehicle-based dual controlled release matrix system as capsule fill
MX2008005474A (en) Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
CA2310407A1 (en) Formulations comprising dissolved paroxetine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201026